Cargando…
Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer
PURPOSE: To evaluate the dosimetric advantages of daily adaptive radiotherapy (DART) in intensity‐modulated proton therapy (IMPT) for high‐risk prostate cancer by comparing estimated doses of the conventional non‐adaptive radiotherapy (NART) that irradiates according to an original treatment plan th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992948/ https://www.ncbi.nlm.nih.gov/pubmed/35045211 http://dx.doi.org/10.1002/acm2.13531 |
_version_ | 1784683810220146688 |
---|---|
author | Tamura, Hiroshi Kobashi, Keiji Nishioka, Kentaro Yoshimura, Takaaki Hashimoto, Takayuki Shimizu, Shinichi Ito, Yoichi M. Maeda, Yoshikazu Sasaki, Makoto Yamamoto, Kazutaka Tamamura, Hiroyasu Aoyama, Hidefumi Shirato, Hiroki |
author_facet | Tamura, Hiroshi Kobashi, Keiji Nishioka, Kentaro Yoshimura, Takaaki Hashimoto, Takayuki Shimizu, Shinichi Ito, Yoichi M. Maeda, Yoshikazu Sasaki, Makoto Yamamoto, Kazutaka Tamamura, Hiroyasu Aoyama, Hidefumi Shirato, Hiroki |
author_sort | Tamura, Hiroshi |
collection | PubMed |
description | PURPOSE: To evaluate the dosimetric advantages of daily adaptive radiotherapy (DART) in intensity‐modulated proton therapy (IMPT) for high‐risk prostate cancer by comparing estimated doses of the conventional non‐adaptive radiotherapy (NART) that irradiates according to an original treatment plan through the entire treatment and the DART that uses an adaptive treatment plan generated by using daily CT images acquired before each treatment. METHODS: Twenty‐three patients with prostate cancer were included. A treatment plan with 63 Gy (relative biological effectiveness (RBE)) in 21 fractions was generated using treatment planning computed tomography (CT) images assuming that all patients had high‐risk prostate cancer for which the clinical target volume (CTV) needs to include prostate and the seminal vesicle (SV) in our treatment protocol. Twenty‐one adaptive treatment plans for each patient (total 483 data sets) were generated using daily CT images, and dose distributions were calculated. Using a 3 mm set‐up uncertainty in the robust optimization, the doses to the CTV, prostate, SV, rectum, and bladder were compared. RESULTS: Estimated accumulated doses of NART and DART in the 23 patients were 60.81 ± 3.47 Gy (RBE) and 63.24 ± 1.04 Gy (RBE) for CTV D99 (p < 0.01), 62.99 ± 1.28 Gy (RBE) and 63.43 ± 1.33 Gy (RBE) for the prostate D99 (p = 0.2529), and 59.07 ± 5.19 Gy (RBE) and 63.17 ± 1.04 Gy (RBE) for SV D99 (p < 0.001). No significant differences were observed between NART and DART in the estimated accumulated dose for the rectum and bladder. CONCLUSION: Compared with the NART, DART was shown to be a useful approach that can maintain the dose coverage to the target without increasing the dose to the organs at risk (OAR) using the 3 mm set‐up uncertainty in the robust optimization in patients with high‐risk prostate cancer. |
format | Online Article Text |
id | pubmed-8992948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89929482022-04-13 Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer Tamura, Hiroshi Kobashi, Keiji Nishioka, Kentaro Yoshimura, Takaaki Hashimoto, Takayuki Shimizu, Shinichi Ito, Yoichi M. Maeda, Yoshikazu Sasaki, Makoto Yamamoto, Kazutaka Tamamura, Hiroyasu Aoyama, Hidefumi Shirato, Hiroki J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: To evaluate the dosimetric advantages of daily adaptive radiotherapy (DART) in intensity‐modulated proton therapy (IMPT) for high‐risk prostate cancer by comparing estimated doses of the conventional non‐adaptive radiotherapy (NART) that irradiates according to an original treatment plan through the entire treatment and the DART that uses an adaptive treatment plan generated by using daily CT images acquired before each treatment. METHODS: Twenty‐three patients with prostate cancer were included. A treatment plan with 63 Gy (relative biological effectiveness (RBE)) in 21 fractions was generated using treatment planning computed tomography (CT) images assuming that all patients had high‐risk prostate cancer for which the clinical target volume (CTV) needs to include prostate and the seminal vesicle (SV) in our treatment protocol. Twenty‐one adaptive treatment plans for each patient (total 483 data sets) were generated using daily CT images, and dose distributions were calculated. Using a 3 mm set‐up uncertainty in the robust optimization, the doses to the CTV, prostate, SV, rectum, and bladder were compared. RESULTS: Estimated accumulated doses of NART and DART in the 23 patients were 60.81 ± 3.47 Gy (RBE) and 63.24 ± 1.04 Gy (RBE) for CTV D99 (p < 0.01), 62.99 ± 1.28 Gy (RBE) and 63.43 ± 1.33 Gy (RBE) for the prostate D99 (p = 0.2529), and 59.07 ± 5.19 Gy (RBE) and 63.17 ± 1.04 Gy (RBE) for SV D99 (p < 0.001). No significant differences were observed between NART and DART in the estimated accumulated dose for the rectum and bladder. CONCLUSION: Compared with the NART, DART was shown to be a useful approach that can maintain the dose coverage to the target without increasing the dose to the organs at risk (OAR) using the 3 mm set‐up uncertainty in the robust optimization in patients with high‐risk prostate cancer. John Wiley and Sons Inc. 2022-01-19 /pmc/articles/PMC8992948/ /pubmed/35045211 http://dx.doi.org/10.1002/acm2.13531 Text en © 2022 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Tamura, Hiroshi Kobashi, Keiji Nishioka, Kentaro Yoshimura, Takaaki Hashimoto, Takayuki Shimizu, Shinichi Ito, Yoichi M. Maeda, Yoshikazu Sasaki, Makoto Yamamoto, Kazutaka Tamamura, Hiroyasu Aoyama, Hidefumi Shirato, Hiroki Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer |
title | Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer |
title_full | Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer |
title_fullStr | Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer |
title_full_unstemmed | Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer |
title_short | Dosimetric advantages of daily adaptive strategy in IMPT for high‐risk prostate cancer |
title_sort | dosimetric advantages of daily adaptive strategy in impt for high‐risk prostate cancer |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992948/ https://www.ncbi.nlm.nih.gov/pubmed/35045211 http://dx.doi.org/10.1002/acm2.13531 |
work_keys_str_mv | AT tamurahiroshi dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT kobashikeiji dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT nishiokakentaro dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT yoshimuratakaaki dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT hashimototakayuki dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT shimizushinichi dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT itoyoichim dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT maedayoshikazu dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT sasakimakoto dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT yamamotokazutaka dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT tamamurahiroyasu dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT aoyamahidefumi dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer AT shiratohiroki dosimetricadvantagesofdailyadaptivestrategyinimptforhighriskprostatecancer |